advertisement
Rho S 9
Showing records 1 to 9 | Display all abstracts from Rho S95666 Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye drops
Kim M
Scientific reports 2021; 11: 17896
96335 Clinical Outcomes After Second-Generation Trabecular Microbypass Stents (iStent inject®) with Phacoemulsification in Korean Patients
Rho S
Ophthalmology and therapy 2021; 10: 1105-1117
96352 Efficacy and safety of newly developed preservative-free latanoprost 0.005% eye drops versus preserved latanoprost 0.005% in open angle glaucoma and ocular hypertension: 12-week results of a randomized, multicenter, controlled phase III trial
Kim JM
International Journal of Ophthalmology 2021; 14: 1539-1547
96335 Clinical Outcomes After Second-Generation Trabecular Microbypass Stents (iStent inject®) with Phacoemulsification in Korean Patients
Lim SH
Ophthalmology and therapy 2021; 10: 1105-1117
96352 Efficacy and safety of newly developed preservative-free latanoprost 0.005% eye drops versus preserved latanoprost 0.005% in open angle glaucoma and ocular hypertension: 12-week results of a randomized, multicenter, controlled phase III trial
Sung KR
International Journal of Ophthalmology 2021; 14: 1539-1547
95666 Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye drops
Jang H
Scientific reports 2021; 11: 17896
96352 Efficacy and safety of newly developed preservative-free latanoprost 0.005% eye drops versus preserved latanoprost 0.005% in open angle glaucoma and ocular hypertension: 12-week results of a randomized, multicenter, controlled phase III trial
Lee JW
International Journal of Ophthalmology 2021; 14: 1539-1547
95666 Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye drops
Rho S
Scientific reports 2021; 11: 17896
96352 Efficacy and safety of newly developed preservative-free latanoprost 0.005% eye drops versus preserved latanoprost 0.005% in open angle glaucoma and ocular hypertension: 12-week results of a randomized, multicenter, controlled phase III trial
Kyung H; Rho S; Kim CY
International Journal of Ophthalmology 2021; 14: 1539-1547
